New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
07:21 EDTGALEGalena announces Defense Department grant for NeuVax clinical trial
Galena announced the Department of Defense will provide funding towards a new clinical trial with NeuVax to prevent breast cancer recurrence in high-risk HER2 3+ patients. The grant, a Breast Cancer Research Program Breakthrough Award, was obtained by Elizabeth A. Mittendorf, M.D., Associate Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center who will oversee the investigator-sponsored trial. Galena will support the trial with study drug and funding and will have access to the research to support ongoing registrational studies. The protocol for the multi-center, prospective, randomized, single-blinded Phase 2 trial is being finalized and is expected to enroll approximately 100 patients with a diagnosis of HER2 3+ breast cancer who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence.
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2015
07:11 EDTGALEGalena announces collaboration with NCI on Phase 2 trial with NeuVax
Subscribe for More Information
September 28, 2015
07:17 EDTGALEGalena presents 'positive' GALE-301 Phase 2a clinical trial data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use